Alimera Sciences Stock Beta
| ALIMDelisted Stock | USD 5.54 0.01 0.18% |
Alimera Sciences fundamentals help investors to digest information that contributes to Alimera Sciences' financial success or failures. It also enables traders to predict the movement of Alimera Stock. The fundamental analysis module provides a way to measure Alimera Sciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Alimera Sciences stock.
Alimera |
Alimera Sciences Company Beta Analysis
Alimera Sciences' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Alimera Sciences Beta | 1.25 |
Most of Alimera Sciences' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alimera Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Alimera Sciences has a Beta of 1.245. This is 44.77% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Alimera Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alimera Sciences' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Alimera Sciences could also be used in its relative valuation, which is a method of valuing Alimera Sciences by comparing valuation metrics of similar companies.Alimera Sciences is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Alimera Sciences will likely underperform.
Alimera Fundamentals
| Return On Equity | -0.35 | |||
| Return On Asset | 0.0098 | |||
| Profit Margin | (0.15) % | |||
| Operating Margin | 0.08 % | |||
| Current Valuation | 360.44 M | |||
| Shares Outstanding | 54.38 M | |||
| Shares Owned By Insiders | 5.34 % | |||
| Shares Owned By Institutions | 86.54 % | |||
| Number Of Shares Shorted | 578.49 K | |||
| Price To Earning | 1.65 X | |||
| Price To Book | 7.77 X | |||
| Price To Sales | 3.02 X | |||
| Revenue | 80.75 M | |||
| Gross Profit | 52 M | |||
| EBITDA | 7.28 M | |||
| Net Income | (20.13 M) | |||
| Cash And Equivalents | 7.86 M | |||
| Cash Per Share | 1.12 X | |||
| Total Debt | 67.4 M | |||
| Current Ratio | 1.30 X | |||
| Book Value Per Share | 0.74 X | |||
| Cash Flow From Operations | (14.26 M) | |||
| Short Ratio | 1.93 X | |||
| Earnings Per Share | 1.05 X | |||
| Target Price | 5.67 | |||
| Number Of Employees | 154 | |||
| Beta | 1.25 | |||
| Market Capitalization | 301.29 M | |||
| Total Asset | 153.52 M | |||
| Retained Earnings | (418.49 M) | |||
| Working Capital | 30.51 M | |||
| Current Asset | 51.6 M | |||
| Current Liabilities | 7.85 M | |||
| Net Asset | 153.52 M |
About Alimera Sciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alimera Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alimera Sciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alimera Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in Alimera Stock
If you are still planning to invest in Alimera Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alimera Sciences' history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |